Literature DB >> 23927549

A founder mutation in COL4A3 causes autosomal recessive Alport syndrome in the Ashkenazi Jewish population.

B D Webb1, T Brandt, L Liu, C Jalas, J Liao, A Fedick, M D Linderman, G A Diaz, R Kornreich, H Trachtman, L Mehta, L Edelmann.   

Abstract

Alport syndrome is an inherited progressive nephropathy arising from mutations in the type IV collagen genes, COL4A3, COL4A4, and COL4A5. Symptoms also include sensorineural hearing loss and ocular lesions. We determined the molecular basis of Alport syndrome in a non-consanguineous Ashkenazi Jewish family with multiple affected females using linkage analysis and next generation sequencing. We identified a homozygous COL4A3 mutation, c.40_63del, in affected individuals with mutant alleles inherited from each parent on partially conserved haplotypes. Large-scale population screening of 2017 unrelated Ashkenazi Jewish samples revealed a carrier frequency of 1 in 183 indicating that COL4A3 c.40_63del is a founder mutation which may be a common cause of Alport syndrome in this population. Additionally, we determined that heterozygous mutation carriers in this family do not meet criteria for a diagnosis of Thin Basement Membrane Nephropathy and concluded that carriers of c.40_63del are not likely to develop benign familial hematuria.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Alport syndrome; Ashkenazi Jewish; COL4A3; founder mutation

Mesh:

Substances:

Year:  2013        PMID: 23927549     DOI: 10.1111/cge.12247

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  7 in total

1.  Natural history of genetically proven autosomal recessive Alport syndrome.

Authors:  Masafumi Oka; Kandai Nozu; Hiroshi Kaito; Xue Jun Fu; Koichi Nakanishi; Yuya Hashimura; Naoya Morisada; Kunimasa Yan; Masafumi Matsuo; Norishige Yoshikawa; Igor Vorechovsky; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2014-03-15       Impact factor: 3.714

Review 2.  Pharmacogenetics in Jewish populations.

Authors:  Yao Yang; Inga Peter; Stuart A Scott
Journal:  Drug Metabol Drug Interact       Date:  2014

Review 3.  Genomic medicine for kidney disease.

Authors:  Emily E Groopman; Hila Milo Rasouly; Ali G Gharavi
Journal:  Nat Rev Nephrol       Date:  2018-01-08       Impact factor: 28.314

4.  Alport syndrome cold cases: Missing mutations identified by exome sequencing and functional analysis.

Authors:  Chiara Chiereghin; Michela Robusto; Antonio Mastrangelo; Pierangela Castorina; Giovanni Montini; Marisa Giani; Stefano Duga; Rosanna Asselta; Giulia Soldà
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

5.  Features of Autosomal Recessive Alport Syndrome: A Systematic Review.

Authors:  Jiwon M Lee; Kandai Nozu; Dae Eun Choi; Hee Gyung Kang; Ii-Soo Ha; Hae Ii Cheong
Journal:  J Clin Med       Date:  2019-02-03       Impact factor: 4.241

6.  Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome.

Authors:  Oliver Gross; Jie Ding; Yanqin Zhang; Jan Böckhaus; Fang Wang; Suxia Wang; Diana Rubel
Journal:  Pediatr Nephrol       Date:  2021-03-27       Impact factor: 3.714

7.  X-Linked and Autosomal Recessive Alport Syndrome: Pathogenic Variant Features and Further Genotype-Phenotype Correlations.

Authors:  Judith Savige; Helen Storey; Hae Il Cheong; Hee Gyung Kang; Eujin Park; Pascale Hilbert; Anton Persikov; Carmen Torres-Fernandez; Elisabet Ars; Roser Torra; Jens Michael Hertz; Mads Thomassen; Lev Shagam; Dongmao Wang; Yanyan Wang; Frances Flinter; Mato Nagel
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.